Webinars
Why KinetiSol Technology is Disrupting Spray Drying
Dave Miller, AustinPx CSO's (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving drug product properties.
Springboarding from these case studies, Dave then focuses on the facility, utilities, and downstream processing requirements for SDDs and contrasts those with the same for KinetiSol.
The second half of dives into the biopharmaceutical performance benefits achievable with KinetiSol when compared to spray drying. This is demonstrated by a series of case studies and explained with rigorous analytical data.
At the end of the lecture, the audience will have a better understanding that KinetiSol is a commercially-ready process not only capable of reproducing SDDs with far less manufacturing complexity and environmental impact, but also with the capability to out design and outperform spray drying.
LEARN MORE ABOUT:
- How to improve the bioavailability of poorly soluble drugs
- How to save time with KinetiSol's fusion-based, solvent free process
- The next generation of amorphous dispersion technology
KinetiSol Technology: Scale-Up Approach
Justin Keen, AustinPx Sr. VP of Operations' talk begins with a discusion on phase-appropriate process development objectives, reviewed as they relate to scale and mode changes as product development evolves to deliver clinical trial material and develop the process design space.
Process parameter and quality attribute relationships, including those for typical pre and post KinetiSol unit operations, will be explored in the context of real-world examples.
LEARN MORE ABOUT:
- How to improve the bioavailability of poorly soluble drugs
- How to save time with KinetiSol's fusion-based, solvent free process
- The next generation of amorphous dispersion technology
Amorphous Solid Dispersions: Development Trends, Challenges and the Future
The pharmaceutical industry is pushing the boundaries of the chemical drug space in search of new and more effective compounds. However, many of these new molecules have properties that make them difficult to develop, including challenging physiochemical characteristics. As a result, the number of poorly soluble drugs in the pipeline is increasing, and there is a growing need for innovation and new technology solutions to produce amorphous solid dispersions.
In this webinar, Dave Miller of AustinPx will explore the latest trends and challenges in the development of poorly soluble molecules. The speaker will also introduce attendees to the KinetiSol™ Technology — a cutting-edge approach that overcomes the limitations of current amorphous dispersion technologies. This innovative and flexible solution revolutionizes the conventional manufacturing process of amorphous solid dispersions, paving the way for improved drug absorption and dosage forms.
Register for this webinar at xtalks.com to learn how this next-generation technology for amorphous solid dispersions can help address the challenges of developing and manufacturing poorly soluble drugs. Learn about the benefits it can provide for the pharmaceutical industry as a whole.